Monday, December 16, 2019 9:19:15 AM
Recent SLRX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:17:10 PM
- Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/22/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:02:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:29:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:25:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 09:13:07 PM
- Salarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing Expenses • GlobeNewswire Inc. • 02/22/2024 01:00:00 PM
- Salarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein Degraders • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment • GlobeNewswire Inc. • 01/03/2024 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:04:46 PM
- Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program • GlobeNewswire Inc. • 11/07/2023 01:30:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 10/27/2023 07:57:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2023 09:09:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 08:14:41 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/10/2023 08:13:50 PM
- Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/10/2023 08:05:00 PM
- Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources • GlobeNewswire Inc. • 08/08/2023 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2023 01:22:11 PM
- Salarius Pharmaceuticals Receives FDA Clearance of SP-3164 Investigational New Drug Application to Begin a Phase 1 Clinical Trial in Relapsed/Refractory Non-Hodgkin Lymphoma Patients • GlobeNewswire Inc. • 07/11/2023 12:30:00 PM
- Salarius Pharmaceuticals Presents SP-3164 Targeted Protein Degrader Preclinical Data at the European Hematology Association 2023 Hybrid Congress • GlobeNewswire Inc. • 06/12/2023 12:00:00 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM